

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Regorafenib for the treatment of metastatic colorectal cancer following prior treatment for metastatic disease

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During the draft scope consultation, a consultee organisation noted that because regorafenib is taken orally, there may be an adverse impact on people who cannot swallow tablets.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

Consultees at the scoping workshop did not consider this to be an equality issue.

If a technology appraisal results in positive recommendations for a particular technology, there may be situations where a person cannot receive the technology, for example contraindications. For any other reasons, the Appraisal Committee can explore if there are additional recommendations and adjustments that can be made in order to enable such persons to receive the recommended technology.
--

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change to the draft scope has been agreed to highlight potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues were identified during the scoping process.

Approved by Associate Director (name): Elisabeth George

Date: 30 05 13